Cancer Survivorship Improvements in cancer screening, early detection, and treatment are
resulting in increased numbers of patients cured of cancer. These persons face a wide …

Hodgkin lymphoma (HL) is a unique hematopoietic neoplasm characterized by cancerous
Reed‐Sternberg cells in an inflammatory background. Patients are commonly diagnosed …

We report a T cell lymphoma (TCL) occurring 3 months after anti-CD19 chimeric antigen
receptor (CAR) T cell immunotherapy for non-Hodgkin B cell lymphoma. The TCL was …

Unanswered questions following reports of secondary malignancies after CAR-T cell therapy |
Nature Medicine Skip to main content Thank you for visiting nature.com. You are using a browser …

The crude incidence of Hodgkin lymphoma (HL) in the European Union is 2.3, the mortality
0.4 cases/100000/year. Young adults aged 20–40 years are most often affected. Slightly …

Despite the importance of chemotherapy-associated adverse events in oncology practice
and the broad range of interventions available to mitigate them, limited systematic efforts …

Recent Developments in Radiotherapy | New England Journal of Medicine Skip to main content
The New England Journal of Medicine homepage Advanced Search SEARCH SPECIALTIES …

Purpose Patients who receive combined modality treatment for stage I and II Hodgkin
lymphoma (HL) have an excellent outcome. Early response evaluation with positron …

Simple Summary Adolescent and young adult (AYA) cancer patients, those who are
diagnosed with cancer for the first time at the age of 15–39 years, are recognized as a …

Background Combined-modality treatment consisting of chemotherapy and consolidation
radiotherapy is standard of care for patients with early-stage unfavourable Hodgkin …